Life Sciences Archive » June, 2022

Life Sciences - June, 2022

308 articles

• We're Not All Textualists Now, Kagan Warns In Climate Dissent
• SF Says Pharmaceutical Cos. Created City's Opioid Crisis
• Opioid Distributors Headed To 2nd W.Va. Nuisance Trial
• Justices Stoke Care Woes For Tribes, Native Women Post-Roe
• Justices' Patent Eligibility Denial Won't End Fight For Clarity
• Endo 'Made Out Like A Bandit' With Opana Deal, Buyers Say
• Thomas Dissents On Denial Of NY Health Worker Vax Case
• IP Forecast: Apple Foe Looks To Revive Axed $308M Verdict
• Juul Buyers Win Cert. For 4 Classes In Vape MDL
• Gov't Contracts Of The Month: Space, Nuclear And Drug Deals
• No Stick In Dollar General's Pain Relief Patches, Suit Says
• Pa. Co. Says Distributor Lied To Land $5.5M COVID Test Deal
• Ex-Mich. Gov. Pleads 5th In Flint Trial Appearance
• 3 Firms Help Blueprint Medicine Get $1.25B Investment
• HHS Issues Guidance On Abortion Patient Privacy After Dobbs
• In COVID, Can PREP Act Protection Extend To Patent Suits?
• Ethics Considerations For Attorneys Joining Nonprofit Boards
• Fla. Judge Says 15-Week Abortion Ban Is Unconstitutional
• Ohio AG Says 6-Week Abortion Ban Should Remain In Place
• Ex-Mich. Gov. Claims No Memory On Aspects Of Flint Crisis
• Juul Says Politics Drove FDA Ban, Seeks To Extend Stay
• Fla. Physical Therapy Clinic Workers Sentenced For Fraud
• NJ Lawmakers Pass Post-Dobbs Abortion Rights Measures
• Review Of Emergent's $325M Smallpox Drug Deal Extended
• High Court's Opioid Ruling Shows Limits Of CSA's Reach
• HHS Watchdog Sees Kickback Concern In Eye Care Programs
• Private Hospital Deal Challenge Best Left To Feds, Judge Says
• Ireland Examinership Becoming Critical In Int'l Insolvency
• What Maine's Recent PFAS Crackdown Means For Companies
• Arch Finalizes $3B Fund To Spur Revolutionary Technology
• Change Could Be Coming To Patent Suit Volume In Texas
• The State Of Abortion Legal Challenges Around The US
• Ohio Abortion Clinics Turn To State High Court After Dobbs
• Texas AG Investigates Walmart's Opioid Sales Practices
• High Court's CSA Decree Augurs Opioid Upheaval For DOJ
• Flint Jury To Hear From Ex-Gov. After Court Quashes Charges
• 6th Circ. Lifts Block On Tenn. Abortion Restriction
• USPTO Issues Report On Patent Eligibility Comments
• 2nd Circ. Ruling Highlights ERISA Determination Deadlines
• Becerra Says 'All Options Are On The Table' After Dobbs
• Recent Trade Secret Cases Show Sentencing Disparities
• Chancery Urged To Consider Firms' Bid To Lead Ionis Suit
• Warby Parker Escapes 1-800 Contacts' Search Engine TM Row
• Alcon Eye-Drop Patents Survive Invalidity Appeal
• Texas Judge Freezes Enforcement Of Pre-Roe Abortion Ban
• As Opioid Trial Ends, Judge Jokes Of 'Generous' Time Limits
• Opioid Distributors Cut $250M Deal With Holdout Okla. AG
• Balwani's Trial Features Tears, Tension And Holmes' Shadow
• Cannabis Bill Roundup: NJ Sen. Eyes Legalizing Hallucinogen
• Catching Up With Delaware's Chancery Court
• Justices Should Resolve FCA Cases' Rule 9(b) Circuit Split
• Ditching Live Testimony For Declarations Is Risky, Attys Say
• Humana Wants To Add Federal Antitrust Claims To Zetia Case
• Trade Secret Suit Over Anesthetic's Cocaine Ingredient Settled
• Supreme Court Won't Review Vascepa Patent Case
• Nomad Health Raises $105M To Grow Traveling Jobs Program
• Utah, Louisiana Abortion Bans Blocked, For Now
• High Court Won't Hear $87M Monsanto Roundup Appeal
• Justices Won't Hear Anthem, Express Scripts Drug Price Fight
• Prescriber Intent Matters In Opioid Cases, High Court Rules
• CareTech To Be Taken Over By Founders In £870M Deal
• Calif. Bank & Trust To Pay $14M To End Claims It Aided Scam
• Abortion Questions Swirl Over Health Attys In Post-Roe World
• Bristol-Myers Can't Dodge Celgene Investors' Drug Delay Suit
• Judge Won't Lift Stay In Masimo Patent Fight Against Apple
• Joint Juice Slams 'Staggering' $141M Ask For False Ad Verdict
• 'Trust Your Eyes,' Feds Urge As Balwani Charges Go To Jury
• NH Medical Society Denounces Insurers' COVID-19 Science
• Dr. Reddy's Gets $72M In Generic Suboxone Settlement
• Juul Wants Okla. Tribe's Nuisance, Product Safety Claims Cut
• Retailers Cut Midtrial Deal With Impax In Opana Delay Case
• Beware Arbitration Clauses That May Bar Inter Partes Review
• Gov't Gets 30 More Days To Review China Tariff Comments
• 3rd Judge On NYC Vax Case Refuses To Step Down
• Health Hires: Arnold & Porter, Arcellx
• Now's The Time To Address Archaic Law School Curricula
• DC Circ. Blocks Enforcement Of FDA's Juul Vape Ban
• The Case For Company-Directed Offensive ESG Litigation
• Supreme Court Overturns Roe v. Wade
• Balwani Rips Feds' 'Incomplete' Case As Trial Nears End
• The Attys Who Took America To Abortion Rights Turning Point
• Pot Advocates Ask 8th Circ. To Put Neb. Election Law On Ice
• Orrick Hires 2 Trial Attys From BakerHostetler
• Lawmakers Warn DOJ Of Brewing Baby Formula-PE Deal
• 3 Firms Usher Radius Health Off Public Market In $890M Deal
• PTAB Refuses Post-Grant Reviews Of 2 Psilocybin Patents
• Abbott Must Face Suit Over Anticonvulsant Birth Defect Risks
• The Unique Nature Of COVID-Era Patent Procurement Trends
• Cyprus Mines Wins Ch. 11 Stay Of Actions Against Parent
• F-Star Therapeutics Agrees To $161M Sino Biopharm Takeover
• FDA Orders Juul E-Cigs Off Shelves
• Lessons From Lawyer Fee-Sharing Agreements Gone Wrong
• Crowell & Moring Adds Stein Mitchell Health Care Litigator
• Balwani's Atty Tells Jury Romance With Holmes Not A Crime
• Ex-Pharma Exec Cops To Insider Trading With Former CFO
• PTAB Nixes Patent Claims For Device To Measure Blood Clots
• Pharmacies' Surescripts Antitrust Case Survives Dismissal
• LeClairRyan Bankruptcy Highlights Pass-Through Tax Issue
• SuperValu Urges High Court Not To Revive FCA Case
• DOJ Official Confirms CCO Certs. Are New Settlement Staple
• 2nd Circ. Got High Court Order Right, Chinese Exporters Say
• Imerys, Cyprus Don't Need To Share Docs With Insurers
• Robbins Geller Seeks Third Of $15M OvaScience Settlement
• Kirkland Guides PE Firm's £650M Acquisition Of Lab Tech Co.
• Fed. Circ. Reverses Initial Panel To Find Gilenya IP Invalid
• Feds Portray Balwani As Holmes' Partner In Crime In Closings
• FDA Seeks To Cap Cigarettes' Nicotine Content
• New Bill Would Create Joint USPTO-FDA Task Force
• Judge Approves $45M Roundup False Ad Deal
• Philips Knew Of CPAP Foam Issues In 2015, Device Users Say
• Potential Next Steps For DOJ's COVID-19 Fraud Enforcement
• Medical Imaging Co. Says Swiss Award Was Marred By Fraud
• Revlon Case Opens, And LATAM Lands Its Ch. 11 Plan
• 8 Steps To Creating A Legal Ops Technology Road Map
• 20 States Ask 5th Circ. To Block Biden's Contractor Vax Order
• Importers, USTR Wrestle Over Deadline In China Tariff Case
• Catching Up With Delaware's Chancery Court
• High Court Won't Review $25M Monsanto Roundup Verdict
• Will BigLaw Regret Its Hiring Spree As The Economy Softens?
• The Law360 400: Tracking The Largest US Law Firms
• FDA Greenlights Moderna, Pfizer Jabs For Kids 6 Mos. And Up
• WTO Vax Patent Deal Seen As Doing Little To Boost Access
• Bayer Notches 4th Trial Win Over Roundup Weedkiller
• Fintiv Denials Are Down, But Bill Banning Them Still Has Teeth
• Teligent's Post-Sale Drug Recall Puts Its Ch. 11 Plan In Doubt
• Generic Co. Asks Fed. Circ. To Undo Loss In Takeda IP Fight
• Clarivate Atty Joins Pharma Intelligence As GC
• 6 Firms Guide UK Biotech Startup's $215M SPAC Merger
• WTO Inks Deals On Fisheries, Vaccines After Lengthy Session
• Yale Law Prof Defends Allergan In SF Opioid Trial
• Chevron Deference Still Feels Heat After High Court Reprieve
• Del. Justices Uphold Toss Of Zimmer Biomet Stockholder Suit
• IP Forecast: Cooley To Fight DQ Bid In Tech Patent Row
• 4th Circ. Denies Eli Lilly's Discovery Bid In Novartis IP Feud
• Pa. Court Halts Recall Of Cannabis Vape Products
• Biogen Urges Justices To Review MS Drug Patent Ruling
• Stimwave Gets OK To Tap $12M In Bankruptcy Financing
• FTC Warns Drugmakers, Middlemen Over Rebates
• The Importance Of Data And Data Analysis In Litigation
• Why Medical Product Cos. Must Watch Dobbs Decision
• Aetna Urges 1st Circ. To Toss Conformis Defamation Suit
• It's Time For USPTO To Abandon The NHK-Fintiv Practice
• Insurer Loses Bid To Limit Boston Hotel's Virus Losses
• $60M Catalyst Sale Gutted Company, Del. Investor Suit Says
• Ark. Prof Gets 1 Year For Lying To FBI About China Patents
• CVS Can't Force Drug Pricing Suit Into Arbitration
• Foley & Lardner Atty Joins Network Health As CLO
• Rising Star: Ropes & Gray's Emily Oldshue
• SF Opioid Crisis Not From Allergan's Market Share, Judge Told
• J&J Keeps Victory Over Defective Mesh Claims At 7th Circ.
• DaVita Must Return Rather Than Destroy No-Poach Docs
• Insurers Should Pay For Medical Pot In New Mexico, Suit Says
• Novartis Can't Keep Bristol-Myers Arbitral Award Under Wraps
• Zydus Blasts Takeda's Patent Abuse 'Blueprint' At 3rd Circ.
• CBD Cos. Must Beware COVID Claims Amid Gov't Scrutiny
• Fla. Medical Device Co. Hits Ch. 11 Amid Ex-CEO Litigation
• Objector Tells 11th Circ. Atty Fees Too High In $8M Class Deal
• FDA Panel Backs Moderna, Pfizer Vaccines For Young Kids
• Biotech Farming SPAC Merger Creates $504M Public Co.
• Judge Trims CEO's Bonus Pay At His Last Purdue Hearing
• Feds Hit Nursing Home With FCA Suit Over 'Nonexistent' Care
• Rising Star: Goodwin Procter's William D. Collins
• Wilson Sonsini Adds Cooley Lateral In New Boulder Office
• WTO Summit Extended Amid A Scramble For Consensus
• High Court Rejects Medicare's $1.6B Cut To Hospital Drug Pay
• Fla. Pharmacy Owner Gets 14-Year Sentence For Mail Fraud
• SF Opioid Judge Not 'Sympathetic' To City's Scheduling Issue
• 'Huge Problem': FDA Leaders Fear Collapsing Trust In Agency
• Bristol-Myers Urges Justices To Ax 'Impossible' Patent Rule
• Impax Got Earliest Possible Generic Opana Entry, Jury Hears
• 'It's Time To Rethink Everything,' Vidal Says
• Kentucky Gov. Creates Medical Cannabis Advisory Group
• NY Panel Upholds Botanical Garden's Virus Coverage Win
• 8th Circ. Won't Revive Suit Over Surgical Tool IP
• Remand Denial Raises Question In W.Va. Opiate Litigation
• Bristol-Myers Sues To Block Rival's Generic Leukemia Drug
• J&J Talc Unit Wants Ch. 11 Claims Estimation Process
• 5th Circ. Affirms Toss Of Hospital Workers' Vax Mandate Suit
• Judge OKs Email Service Of Law Firms In Cyprus Mines Suit
• Ice Miller Adds 4-Attorney IP Team From BakerHostetler
• Steps Companies Can Take To Mitigate Privilege Labeling Risk
• Rising Star: DLA Piper's Jessica Wilson
• Amarin Beats Class Claims Of Duping Investors At 3rd Circ.
• Judge Breyer Pitches Law Chat As SF Opioid Trial Nears End
• Ohio Counties Open To Lowering Opioid Damages Request
• Investor Attys Net $22.6M In Dental Supply Antitrust Deal
• Pharma Co. Exec's Wife Inks SEC Deal Over Insider Trading
• GOP Rep. Stokes China Fears Amid COVID IP Waiver Talks
• Takeda Unit Warns Fed. Circ. Antibody Patents At Risk
• NY AG's Opioid Trial Theory Fatally Flawed, Teva Says
• Blade Therapeutics' $353M SPAC Go-Public Deal Called Off
• Texas Judge Won't Toss Vineyards' Suit Against Bayer, BASF
• Catching Up With Delaware's Chancery Court
• Fed. Circ. Revives UMass Skin Care IP Suit Against L'Oreal
• Judge Exits NYC Vaccine Case After Stock Complaints
• Ex-Moderna Public Policy VP Rejoins Epstein Becker
• Hemp Equipment Co. Fights Bid To Ditch Counterclaims
• Labcorp Accused Of Bias Over Medical Pot In Job Drug Test
• Rising Star: Butler Snow's Susanna Moldoveanu
• Justices Spurn Insys Exec's Appeal In Landmark Opioid Case
• US Taking Long View On Reshaping WTO As Summit Opens
• Opioid Judge Disavows 'Unfair' Atty Fees But Still Draws Fire
• GoodRx Investors' Claims Over IPO Get Axed For Good
• 9th Circ. Mulls If Valid Patents Moot FCA Suit Against Bausch
• Fed. Circ. Eyes Eligibility Of Stanford's Transplant Testing IP
• States Get $853K In Pared Down Shkreli Antitrust Case Fees
• Bayer Notches 3rd Roundup Trial Win With Missouri Verdict
• Balwani Can't Get Jury Edge Over Lost Theranos Database
• Trader Pleads Guilty In Biotech Co. Stock Spoofing Scheme
• Sens. Urge Vidal To Block Drug Patent 'Thickets' Early
• What Litigation Funding Disclosure In Delaware May Look Like
• Zymeworks Takes Poison Pill To Block Hostile Bid
• NYC Teachers Want Judge Off Vax Case Due To Pfizer Stock
• Del. Court Denies Ex-CEO GenapSys Committee Access
• How To Avert Unlawful Poaching Amid Rising Antitrust Risks
• State Crackdown On Deceptive Ads For Drug Suits Is Welcome
• Rising Star: Baker McKenzie's Khelin Aiken
• Hogan Lovells Adds Foley Hoag M&A Co-Chair In Boston
• IP Forecast: '60 Seconds' Car Copyright Saga Rolls Into LA
• Balwani Rests After Testimony On Lost Theranos Database
• FTC Eyes Drugmaker Rebates Boosting Higher Cost Drugs
• Shipping Co. Wants Suit Over $200M Accident Award Nixed
• FDA Answers Hair Loss Drug Petition, Group Drops Suit
• Jury Clears Reckitt Benckiser In Trade Secret, Fraud Trial
• FTC Judge Says Lives At Stake In Cancer Test Deal Challenge
• FDA Medical Device Cyber Guidance Protects Patients, Cos.
• Ex-Illumina CPA Ducks Prison After Insider-Trading Testimony
• Reed Smith Litigator Joins Jackson Walker In Houston
• Tech Pro Becomes Latest Perkins Coie Atty To Jump To MoFo
• Drug Industry Didn't Create Nation's Opioid Crisis, Judge Told
• FTC Probe Into Rx Middlemen May Spark Industry Shakeup
• Costlier Loans Clear Mallinckrodt For Ch. 11 Exit Next Week
• Blood Plasma Co.'s $10M BIPA Deal Gets Early Blessing
• Cyprus Sues In Del. Ch. 11 To Block 'Alter Ego' Talc Suits
• Fed. Circ. Affirms PTAB Ax Of Omni MedSci IP In Apple Row
• Medtronic Hernia Mesh Suits Transferred To Mass. By JPML
• Amgen, Juno And The Fate Of Functional Genus Claims
• Hartford Must Pay Medline Legal Fees To End Federal Case
• Joint Juice Hit With $1.49M NY Class False Ad Verdict
• Rimon Opens Orlando Office With Life Science Atty
• DEA Change In Opioid Policy Created Confusion, Judge Hears
• Don't Trust DOJ's 'Pure Ipse Dixit' On FCA Split, Justices Told
• AGs' Disgorgement Claim Axed In Drug Price-Fixing Case
• DEA Says Pot Researchers' Suit Belongs In Circ. Court
• Tivity Investors Win Cert. In Suit Over $1.3B Nutrisystem Deal
• FDA Chafes At Drugmaker's Graphic Design In Promo Piece
• Mylan Takes Actelion Drug IP Fight To Fed. Circ.
• FTC To Probe Pharma Middlemen Over High Drug Prices
• WTO Leaders Make Push For Deals Ahead Of Summit
• Wis. Judge Blocks Tribal Court Opioid Suit Against McKinsey
• Merck General Counsel Added To Biotech Company's Board
• 2nd Circ. Gives Salesman Another Shot At Hartford ERISA Suit
• FDA Panel Backs Novavax's COVID-19 Vaccine
• Goodwin Boosts DC Litigation Team With False Claims Act Pro
• Ex-Eli Lilly Worker Sues Over 'Serious' Manufacturing Issues
• GW Pharma Wants Judge To Nix Investor Suit Over $7.2B Deal
• 3rd Juror Sick As Balwani Trial Nears End Without Holmes
• Bristol-Myers Inks $10.8M Deal In Direct Buyers' Antitrust Suit
• Catching Up With Delaware's Chancery Court
• 5th Circ. Doubts Requests For Health Care Vax Opinion
• Understanding FDA's Prescription Drug Promotion Priorities
• 9th Circ. Securities Fraud Ruling Bodes Well For Pharma Cos.
• Taking A Long-Term View On Russia's Patent Landscape
• 5th Circ. Mulls Sending Hospital Vax Suit To Texas Justices
• Moderna Can't Punt To Gov't In COVID-19 Vax Suit, Cos. Say
• How In-House Legal Leaders Can Drive Corporate Growth
• McKesson Seeks Early Appeal In Opioid Coverage Dispute
• Chancery Stays Suit Over Drug Trial Disclosure Failures
• Simpson Thacher Adds Goodwin Securities Pro In Palo Alto
• The Future Of Legal Cannabis In The Nation's Capital
• A Look At Public's Divergent Views On New Merger Guidelines
• Zoetis Must Face Suit Over Horse's Death From Antibiotics
• Ropes & Gray, Goodwin Steer $1.5B Pharmacy Tech Co. Deal
• Illumina Wants 'Indefensible' $334M DNA IP Verdict Tossed
• Del. Judge Recommends Keeping Blood Analyzer IP Row Alive
• Chancery Tosses Remainder Of Suit Against Vaccine Firm
• Nostrum Loses Asthma Drug FDA Fight At DC Circ.
• Wash. High Court Says Drugmakers Need Not Warn Patients
• NY Cop Sues City Over Vax Mandate That Exempts Athletes
• HHS' Free Genetic Testing Opinion Raises Questions For Cos.
• Attorneys Should Tread Carefully On Job Counteroffers
• Ex-Quest Workers Seek Cert. In ERISA Class Action
• Kirkland, Cooley Pilot Bristol-Myers' $4B Cancer Drug Co. Buy
• Walgreens Exec Faces Tough Queries From SF Opioid Judge
• Panel Rejects Opioid MDL Expansion Despite 'Flood Of Cases'
• Insider Trading Claims In Sanofi-Bioverativ Suit Move Forward
• PTAB Axes 2 Masimo Corp. Patents Involved In Apple Row
• Goodwin To Pay BioDelivery $850K To Settle Shareholder Suit
• No Atty Fees For Lionbridge After Trade Secrets Win
• 'Overzealous' Claim Not Enough To Redo Teva NY Opioid Trial
• The Future Of Legal Ops: Time To Get Serious About Data
• Conn. Atty Wins New SEC Trial After Judge's Jury Poll Gaffe
• SF Opioid Judge Told Higher Doses Increased Addiction
• Sidley Not Conflicted, NJ Diocese Ch. 11 Moves Forward
• Pfizer Attacks Rival's Claims Over Vaccine Patent In Del.
• Fla. Abortion Providers Sue State Over 15-Week Ban
• Conn. Atty Can't Flip Fraud Verdict Over Jury Instructions
• Precigen Investors' Gas Fraud Suit Gets Axed, For Now
• Pot Co. Aphria Urges Judge To Deny Investors' Class Cert. Bid
• Zydus Defeats 209-Patient Suit Over Heart Pill Marketing
• 5 Observations On Solicitor General's Patent Eligibility Brief
• Calif. Panel Reverses Zimmer's $7.7M Hip Implant Retrial Loss
• Synthego Gets PTAB To Review 2 Full CRISPR Patents
• Cannabis Research Lab Pushes Back On DEA Bid To Toss Suit
• Insight Into California's Increasing Cannabis Litigation
• Examiner Gets $950K In Fee Cuts In J&J Talc Unit's Ch. 11
• Dobbs Draft Hints At Bold Court With Harvard Case On Deck
• SF Opioid Judge Irked At Allergan Argument Against Expert